Equities analysts predict that Blueprint Medicines Corp (NASDAQ:BPMC) will report sales of $2.14 million for the current quarter, Zacks Investment Research reports. Four analysts have issued estimates for Blueprint Medicines’ earnings, with the lowest sales estimate coming in at $1.13 million and the highest estimate coming in at $3.44 million. Blueprint Medicines posted sales of $1.63 million in the same quarter last year, which suggests a positive year over year growth rate of 31.3%. The firm is expected to report its next earnings results on Wednesday, February 20th.
According to Zacks, analysts expect that Blueprint Medicines will report full-year sales of $45.64 million for the current fiscal year, with estimates ranging from $44.61 million to $46.93 million. For the next year, analysts forecast that the business will post sales of $9.03 million, with estimates ranging from $3.62 million to $20.00 million. Zacks’ sales averages are a mean average based on a survey of research firms that that provide coverage for Blueprint Medicines.
BPMC has been the subject of a number of recent analyst reports. Wedbush reaffirmed an “outperform” rating and set a $103.00 price target on shares of Blueprint Medicines in a report on Monday, January 7th. BidaskClub raised Blueprint Medicines from a “hold” rating to a “buy” rating in a report on Tuesday, January 15th. Zacks Investment Research downgraded Blueprint Medicines from a “hold” rating to a “sell” rating in a report on Tuesday, January 15th. ValuEngine downgraded Blueprint Medicines from a “strong-buy” rating to a “buy” rating in a report on Wednesday, January 2nd. Finally, Cowen reaffirmed a “buy” rating on shares of Blueprint Medicines in a report on Thursday, November 15th. One analyst has rated the stock with a sell rating, six have issued a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $103.25.
Shares of NASDAQ BPMC opened at $72.53 on Tuesday. The stock has a market cap of $3.21 billion, a price-to-earnings ratio of -18.52 and a beta of 1.61. The company has a quick ratio of 10.05, a current ratio of 10.05 and a debt-to-equity ratio of 0.03. Blueprint Medicines has a 1 year low of $44.58 and a 1 year high of $109.00.
Blueprint Medicines Company Profile
Blueprint Medicines Corporation, a biopharmaceutical company, develops drugs of small molecule kinase inhibitors that target genomic drivers in various cancers and a rare genetic disease. Its lead drug candidates include avapritinib, which is in Phase I clinical trials that targets KIT Exon 17 mutant proteins and PDGFRa D842V mutations, that are drivers of cancer and proliferative disorders, including gastrointestinal stromal tumors and systemic mastocytosis; and BLU-554, which is in Phase I clinical trials an orally available, potent, and irreversible inhibitor of the kinase FGFR4 that is activated in a defined subset of patients with hepatocellular carcinoma.
Featured Story: Why is cost of goods sold important?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Blueprint Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blueprint Medicines and related companies with MarketBeat.com's FREE daily email newsletter.